Clinical Trial: Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108699) titled 'Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)' on July 31.

Brief Summary: To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.

Study Start Date: Aug. 13

Study Type: INTERVENTIONAL

Condition: Chronic Obstructive Pulmonary Disease (COPD)

Intervention: DRUG: HSK39004 Dry Powder Inhaler-0.75mg

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day

DRUG: HSK39004 Dry Powder Inhaler-1.5mg

HSK39004 Dry Powder Inhaler: In...